Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNT: Carboplatin vs Docetaxel in Triple Negative Breast Cancer
NCT00532727Phase 3Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- Jan 2008
- Primary completion
- Mar 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin in triple-negative breast cancer (TNBC), sponsored by The Institute of Cancer Research. Primary endpoint: Objective Response Rate at 18 weeks. Status: unknown.
02
Drugs
carboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00532727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00532727.